Man Group plc Invests $8.71 Million in Enovis Corporation $ENOV

Man Group plc bought a new position in Enovis Corporation (NYSE:ENOV) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 420,821 shares of the company’s stock, valued at approximately $8,711,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its holdings in Enovis by 1.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock valued at $90,156,000 after buying an additional 51,201 shares in the last quarter. Rubric Capital Management LP purchased a new stake in shares of Enovis during the 3rd quarter worth approximately $83,435,000. Paradigm Capital Management Inc. NY boosted its position in shares of Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after acquiring an additional 732,917 shares during the last quarter. River Road Asset Management LLC boosted its position in shares of Enovis by 3.2% during the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after acquiring an additional 46,289 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Enovis by 38.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock valued at $24,430,000 after purchasing an additional 287,687 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ENOV has been the topic of several research reports. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Canaccord Genuity Group lowered their price objective on shares of Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, August 17th. Evercore set a $32.00 price objective on shares of Enovis in a research note on Monday, July 6th. UBS Group restated a “buy” rating and issued a $51.00 target price (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Finally, BTIG Research upped their target price on shares of Enovis from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.29.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert bought 1,200 shares of Enovis stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $21.62 per share, with a total value of $25,944.00. Following the completion of the purchase, the insider owned 51,840 shares in the company, valued at $1,120,780.80. The trade was a 2.37% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have acquired a total of 4,200 shares of company stock valued at $92,084 over the last quarter. Corporate insiders own 2.90% of the company’s stock.

Enovis Stock Performance

NYSE ENOV opened at $24.91 on Friday. The business’s 50 day moving average price is $25.60 and its 200-day moving average price is $24.25. Enovis Corporation has a fifty-two week low of $19.14 and a fifty-two week high of $34.28. The company has a market cap of $1.44 billion, a P/E ratio of -1.29 and a beta of 1.34. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.Enovis’s revenue was up 3.2% on a year-over-year basis. During the same period last year, the company earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts predict that Enovis Corporation will post 3.15 earnings per share for the current year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.